EPCORITAMAB-BYSP for Diffuse large b-cell lymphoma recurrent: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

There are 26 adverse event reports in the FDA FAERS database where EPCORITAMAB-BYSP was used for Diffuse large b-cell lymphoma recurrent.

Most Reported Side Effects for EPCORITAMAB-BYSP

Side Effect	Reports	%	Deaths	Hosp.
Cytokine release syndrome	369	37.7%	136	87
Diffuse large b-cell lymphoma	206	21.1%	112	25
Diffuse large b-cell lymphoma refractory	198	20.3%	101	25
Pyrexia	79	8.1%	29	26
Immune effector cell-associated neurotoxicity syndrome	77	7.9%	34	28
Covid-19	39	4.0%	18	18
Neutrophil count decreased	35	3.6%	11	12
Hypogammaglobulinaemia	32	3.3%	7	8
Platelet count decreased	32	3.3%	11	11
Cytomegalovirus infection	31	3.2%	10	12
Pneumonia	29	3.0%	16	13
Cytomegalovirus infection reactivation	26	2.7%	7	5
Death	25	2.6%	25	4
Malignant neoplasm progression	24	2.5%	10	1
Hypoalbuminaemia	20	2.0%	8	4